JPH11507558A - 自然分泌細胞外マトリックスのための組成物及び方法 - Google Patents
自然分泌細胞外マトリックスのための組成物及び方法Info
- Publication number
- JPH11507558A JPH11507558A JP9501790A JP50179097A JPH11507558A JP H11507558 A JPH11507558 A JP H11507558A JP 9501790 A JP9501790 A JP 9501790A JP 50179097 A JP50179097 A JP 50179097A JP H11507558 A JPH11507558 A JP H11507558A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- extracellular matrix
- tissue
- secreted
- skeleton
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 108
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 108
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 105
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims description 49
- 230000003248 secreting effect Effects 0.000 title claims description 22
- 210000004027 cell Anatomy 0.000 claims abstract description 140
- 210000001519 tissue Anatomy 0.000 claims abstract description 76
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 102000008186 Collagen Human genes 0.000 claims description 89
- 108010035532 Collagen Proteins 0.000 claims description 89
- 229920001436 collagen Polymers 0.000 claims description 88
- 210000002950 fibroblast Anatomy 0.000 claims description 44
- 239000000463 material Substances 0.000 claims description 42
- -1 polypropylene Polymers 0.000 claims description 17
- 230000007547 defect Effects 0.000 claims description 12
- 210000002889 endothelial cell Anatomy 0.000 claims description 11
- 230000010261 cell growth Effects 0.000 claims description 9
- 210000001612 chondrocyte Anatomy 0.000 claims description 9
- 239000004793 Polystyrene Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 229920002223 polystyrene Polymers 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 210000002919 epithelial cell Anatomy 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 229920001661 Chitosan Polymers 0.000 claims description 6
- 229920000742 Cotton Polymers 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 239000000020 Nitrocellulose Substances 0.000 claims description 6
- 239000004952 Polyamide Substances 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 230000000968 intestinal effect Effects 0.000 claims description 6
- 229920001220 nitrocellulos Polymers 0.000 claims description 6
- 229920000058 polyacrylate Polymers 0.000 claims description 6
- 229920002647 polyamide Polymers 0.000 claims description 6
- 229920000515 polycarbonate Polymers 0.000 claims description 6
- 239000004417 polycarbonate Substances 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 239000004633 polyglycolic acid Substances 0.000 claims description 6
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 6
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 229920002554 vinyl polymer Polymers 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000004743 Polypropylene Substances 0.000 claims description 5
- 230000002147 killing effect Effects 0.000 claims description 5
- 229920001155 polypropylene Polymers 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 230000002269 spontaneous effect Effects 0.000 claims description 4
- 102000003839 Human Proteins Human genes 0.000 claims description 2
- 108090000144 Human Proteins Proteins 0.000 claims description 2
- 210000004416 odontoblast Anatomy 0.000 claims 5
- 210000000963 osteoblast Anatomy 0.000 claims 5
- 230000002207 retinal effect Effects 0.000 claims 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 5
- 229940058401 polytetrafluoroethylene Drugs 0.000 claims 4
- JRXXLCKWQFKACW-UHFFFAOYSA-N biphenylacetylene Chemical compound C1=CC=CC=C1C#CC1=CC=CC=C1 JRXXLCKWQFKACW-UHFFFAOYSA-N 0.000 claims 2
- 229920000151 polyglycol Polymers 0.000 claims 2
- 239000010695 polyglycol Substances 0.000 claims 2
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical group FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 claims 1
- 239000003356 suture material Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 abstract description 28
- 230000002950 deficient Effects 0.000 abstract 1
- 210000002536 stromal cell Anatomy 0.000 description 43
- 210000003491 skin Anatomy 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 239000002609 medium Substances 0.000 description 19
- 230000012010 growth Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000283690 Bos taurus Species 0.000 description 15
- 239000003102 growth factor Substances 0.000 description 14
- 238000000338 in vitro Methods 0.000 description 14
- 210000004872 soft tissue Anatomy 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 229920001778 nylon Polymers 0.000 description 11
- 239000004677 Nylon Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 239000007943 implant Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108090000631 Trypsin Proteins 0.000 description 8
- 102000004142 Trypsin Human genes 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 102000016359 Fibronectins Human genes 0.000 description 7
- 108010067306 Fibronectins Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000002356 single layer Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 229940096422 collagen type i Drugs 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 102000007000 Tenascin Human genes 0.000 description 4
- 108010008125 Tenascin Proteins 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000003416 augmentation Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000007758 minimum essential medium Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000001187 Collagen Type III Human genes 0.000 description 3
- 108010069502 Collagen Type III Proteins 0.000 description 3
- 208000032170 Congenital Abnormalities Diseases 0.000 description 3
- 102000004237 Decorin Human genes 0.000 description 3
- 108090000738 Decorin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000007790 scraping Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 102000007299 Amphiregulin Human genes 0.000 description 2
- 108010033760 Amphiregulin Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 101150021185 FGF gene Proteins 0.000 description 2
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002570 interstitial cell Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003658 microfiber Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 102000037983 regulatory factors Human genes 0.000 description 2
- 108091008025 regulatory factors Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000012421 spiking Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 101100394030 Dictyostelium discoideum gxcB gene Proteins 0.000 description 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000002325 Funnel Chest Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027982 Morphoea Diseases 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000005248 Vocal Cord Paralysis Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000501 collagen implant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 208000016809 linear scleroderma Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000004788 neurological cell Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- UYDLBVPAAFVANX-UHFFFAOYSA-N octylphenoxy polyethoxyethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCO)C=C1 UYDLBVPAAFVANX-UHFFFAOYSA-N 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000002356 skeleton Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001590 sorbitan monolaureate Substances 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000013637 submucosal cleft palate Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0059—Cosmetic or alloplastic implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/10—Hair or skin implants
- A61F2/105—Skin implants, e.g. artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.(a)細胞増殖に好適な条件下で、所定の時間、3次元骨格上で細胞を培養し 、接種された骨格上に細胞外マトリックスを分泌させて、コートされた骨格を作 製し、 (b)該細胞を死滅させ、そして、 (c)該細胞及び細胞片を除去する ことを含む、自然分泌細胞外マトリックスでコートされた3次元骨格を製造する 方法。 2.前記3次元骨格が、ポリアミド、ポリエステル、ポリスチレン、ポリプロピ レン、ポリアクリル酸塩、ポリビニル化合物、ポリカーボネート、ポリテトラフ ルオロエチレン、サーマノクス、ニトロセルロース、コットン、ポリグリコール 酸、腸線縫合糸材、セルロース、ゼラチン、キトサン、ヒアルロン酸及びデキス トランからなる群より選択される物質から作製される請求項1記載の方法。 3.前記3次元骨格が約150μm〜約220μmの孔隙を有する請求項1記載の方法 。 4.前記細胞外マトリックスが組織特異的細胞により分泌される請求項1記載の 方法。 5.前記細胞外マトリックスが、繊維芽細胞、骨芽細胞、象牙芽細胞、軟骨細胞 、上皮細胞、平滑筋細胞、網膜細胞、内皮細胞、間質細胞からなる群より選択さ れる細胞又はそれらの組み合わせにより分泌される請求項1記載の方法。 6.(a)細胞増殖に好適な条件下で、所定の時間、3次元骨格上で細胞を培養し 、接種された骨格上に細胞外マトリックスを分泌させて、コートされた骨格を作 製し、 (b)該細胞を死滅させ、 (c)該細胞及び細胞片を除去し、そして、 (d)コートされた骨格上に堆積した細胞外マトリックスを回収する ことを含む、自然分泌細胞外マトリックスを製造する方法。 7.前記3次元骨格が、ポリアミド、ポリエステル、ポリスチレン、ポリプロ ピレン、ポリアクリル酸塩、ポリビニル化合物、ポリカーボネート、ポリテトラ フルオロエチレン、サーマノクス、ニトロセルロース、コットン、ポリグリコー ル酸、腸線縫合糸、セルロース、ゼラチン、キトサン、ヒアルロン酸及びデキス トランからなる群より選択される物質から作製される請求項6記載の方法。 8.前記3次元骨格が約150μm〜約220μmの孔隙を有する請求項6記載の方法 。 9.前記自然分泌細胞外マトリックスが組織特異的細胞により分泌される請求項 6記載の方法。 10.前記自然分泌細胞外マトリックスが、繊維芽細胞、骨芽細胞、象牙芽細胞 、軟骨細胞、上皮細胞、平滑筋細胞、網膜細胞、内皮細胞、間質細胞からなる群 より選択される細胞又はそれらの組み合わせにより分泌される請求項6記載の方 法。 11.ヒトタンパク質で構成される自然分泌細胞外マトリックスでコートされた 3次元骨格を含む組成物。 12.前記骨格が、ポリアミド、ポリエステル、ポリスチレン、ポリプロピレン 、ポリアクリル酸塩、ポリビニル化合物、ポリカーボネート、ポリテトラフルオ ロエチレン、サーマノクス、ニトロセルロース、コットン、ポリグリコール酸、 腸線縫合糸、セルロース、ゼラチン、キトサン、ヒアルロン酸及びデキストラン からなる群より選択される物質から作製される請求項11記載の組成物。 13.前記3次元骨格が約150μm〜約220μmの孔隙を有する請求項11記載の 組成物。 14.前記自然分泌細胞外マトリックスが組織特異的細胞により分泌される請求 項11記載の組成物。 15.前記自然分泌細胞外マトリックスが、繊維芽細胞、骨芽細胞、象牙芽細胞 、軟骨細胞、上皮細胞、平滑筋細胞、網膜細胞、内皮細胞、間質細胞からなる群 より選択される細胞又はそれらの組み合わせにより分泌される請求項11記載の 組成物。 16.ヒト自然分泌細胞外マトリックス及び医薬的に許容される担体を含む、組 織欠損の治療のために注射することのできる自然分泌細胞外マトリックス組成 物。 17.前記自然分泌細胞外マトリックスが (a)細胞増殖に好適な条件下で、所定の時間、3次元骨格上で細胞を培養し、接 種された骨格上に細胞外マトリックスを分泌させて、コートされた骨格を作製し 、 (b)該細胞を死滅させ、 (c)該細胞及び細胞片を除去し、 (d)コートされた骨格上に堆積した自然分泌細胞外マトリックスを回収し、そし て、 (e)回収された細胞外マトリックスを医薬的に許容される担体を用いて加工する ことによって製造される請求項16記載の組成物。 18.別の組織又は細胞型により分泌された自然分泌細胞外マトリックスを(d) 工程と(e)工程の間で混合して、コラーゲンI〜V型のそれぞれお互いの比率を 調整する請求項17記載の組成物。 19.前記骨格が、ポリアミド、ポリエステル、ポリスチレン、ポリプロピレン 、ポリアクリル酸塩、ポリビニル化合物、ポリカーボネート、ポリテトラフルオ ロエチレン、サーマノクス、ニトロセルロース、コットン、ポリグリコール酸、 腸線縫合糸、セルロース、ゼラチン、キトサン、ヒアルロン酸及びデキストラン からなる群より選択される物質から作製される請求項16記載の組成物。 20.前記3次元骨格が約150μm〜約220μmの孔隙を有する請求項16記載の 組成物。 21.前記自然分泌細胞外マトリックスが組織特異的細胞により分泌される請求 項16記載の組成物。 22.前記自然分泌細胞外マトリックスが、繊維芽細胞、骨芽細胞、象牙芽細胞 、軟骨細胞、上皮細胞、平滑筋細胞、網膜細胞、内皮細胞、間質細胞からなる群 より選択される細胞又はそれらの組み合わせにより分泌される請求項16記載の 組成物。 23.医薬的に許容される担体中の自然分泌細胞外マトリックスを組織欠損部位 に注射することを含む、組織欠損を修復する方法。 24.前記自然分泌細胞外マトリックスが (a)細胞増殖に好適な条件下で、所定の時間、3次元骨格上で細胞を培養し、接 種された骨格上に細胞外マトリックスを分泌させて、コートされた骨格を作製し 、 (b)該細胞を死滅させ、 (c)該細胞及び細胞片を除去し、 (d)コートされた骨格上に堆積した自然分泌細胞外マトリックスを回収し、そし て、 (e)回収された細胞外マトリックスを医薬的に許容される担体を用いて加工する ことによって製造される請求項23記載の方法。 25.別の組織又は細胞型により分泌された自然分泌細胞外マトリックスを(d) 工程と(e)工程の間で混合して、コラーゲンI〜V型のそれぞれお互いの比率を 調整する請求項23記載の方法。 26.前記骨格が、ポリアミド、ポリエステル、ポリスチレン、ポリプロピレン 、ポリアクリル酸塩、ポリビニル化合物、ポリカーボネート、ポリテトラフルオ ロエチレン、サーマノクス、ニトロセルロース、コットン、ポリグリコール酸、 腸線縫合糸、セルロース、ゼラチン、キトサン、ヒアルロン酸及びデキストラン からなる群より選択される物質から作製される請求項23記載の方法。 27.前記3次元骨格が約150μm〜約220μmの孔隙を有する請求項23記載の 方法。 28.前記自然分泌細胞外マトリックスが組織特異的細胞により分泌される請求 項23記載の方法。 29.前記自然分泌細胞外マトリックスが、繊維芽細胞、骨芽細胞、象牙芽細胞 、軟骨細胞、上皮細胞、平滑筋細胞、網膜細胞、内皮細胞、間質細胞からなる群 より選択される細胞又はそれらの組み合わせにより分泌される請求項23記載の 方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US470,101 | 1995-06-06 | ||
US08/470,101 US5830708A (en) | 1995-06-06 | 1995-06-06 | Methods for production of a naturally secreted extracellular matrix |
PCT/US1996/009482 WO1996039101A1 (en) | 1995-06-06 | 1996-06-06 | Compositions and methods for naturally secreted extracellular matrix |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11507558A true JPH11507558A (ja) | 1999-07-06 |
JP3709487B2 JP3709487B2 (ja) | 2005-10-26 |
Family
ID=23866272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50179097A Expired - Lifetime JP3709487B2 (ja) | 1995-06-06 | 1996-06-06 | 自然分泌細胞外マトリックスのための組成物及び方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5830708A (ja) |
EP (1) | EP0967934B1 (ja) |
JP (1) | JP3709487B2 (ja) |
KR (1) | KR19990022216A (ja) |
AT (1) | ATE290350T1 (ja) |
AU (1) | AU708090B2 (ja) |
CA (1) | CA2223892A1 (ja) |
DE (1) | DE69634454T2 (ja) |
ES (1) | ES2238076T3 (ja) |
NZ (1) | NZ311313A (ja) |
WO (1) | WO1996039101A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004523484A (ja) * | 2000-11-17 | 2004-08-05 | ヴァージニア コモンウェルス ユニバーシティ インテレクチュアル プロパティー ファンデーション | 電気処理されたコラーゲン |
JP2005211099A (ja) * | 2004-01-27 | 2005-08-11 | Olympus Corp | 人工臓器構成材および人工臓器構成体の製造方法および人工臓器 |
JP2010511375A (ja) * | 2005-12-01 | 2010-04-15 | エイジェンシー フォー サイエンス,テクノロジー アンド リサーチ | 組織工学の足場としての三次元再構成細胞外マトリクス |
JP2012508739A (ja) * | 2008-11-14 | 2012-04-12 | ヒストジェン インコーポレイテッド | がんの処置のための細胞外マトリックス組成物 |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6974571B2 (en) * | 1995-03-28 | 2005-12-13 | Thomas Jefferson University | Isolated stromal cells and methods of using the same |
US6284284B1 (en) * | 1995-06-06 | 2001-09-04 | Advanced Tissue Sciences, Inc. | Compositions and methods for production and use of an injectable naturally secreted extracellular matrix |
WO1998036704A1 (en) * | 1997-02-20 | 1998-08-27 | Keller Gregory S | Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects |
US7767452B2 (en) | 1997-02-20 | 2010-08-03 | Kleinsek Don A | Tissue treatments with adipocyte cells |
GB9720987D0 (en) * | 1997-10-01 | 1997-12-03 | Biocure Ltd | A multicellular in vitro assay of angiogenesis |
US6225118B1 (en) | 1997-10-01 | 2001-05-01 | Biocure Limited | Multicellular in vitro assay of angiogenesis |
US6660301B1 (en) | 1998-03-06 | 2003-12-09 | Biosphere Medical, Inc. | Injectable microspheres for dermal augmentation and tissue bulking |
WO1999047186A1 (en) * | 1998-03-18 | 1999-09-23 | University Of Pittsburgh | Chitosan-based composite materials containing glycosaminoglycan for cartilage repair |
US6378527B1 (en) * | 1998-04-08 | 2002-04-30 | Chondros, Inc. | Cell-culture and polymer constructs |
US6428978B1 (en) * | 1998-05-08 | 2002-08-06 | Cohesion Technologies, Inc. | Methods for the production of gelatin and full-length triple helical collagen in recombinant cells |
BR9915476A (pt) * | 1998-11-19 | 2002-01-02 | Organogenesis Inc | Construtos de tecidos feitos por bioengenharia e métodos para a sua produção e utilização |
US7615373B2 (en) | 1999-02-25 | 2009-11-10 | Virginia Commonwealth University Intellectual Property Foundation | Electroprocessed collagen and tissue engineering |
US6662805B2 (en) | 1999-03-24 | 2003-12-16 | The Johns Hopkins University | Method for composite cell-based implants |
US20030007954A1 (en) * | 1999-04-12 | 2003-01-09 | Gail K. Naughton | Methods for using a three-dimensional stromal tissue to promote angiogenesis |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
AU6072200A (en) * | 1999-07-09 | 2001-01-30 | Advanced Tissue Sciences, Inc. | Human naturally secreted extracellular matrix-coated device |
AU7067200A (en) * | 1999-08-23 | 2001-03-19 | Organogenesis Inc. | Skin care compositions and treatments |
US20080267923A2 (en) * | 1999-11-05 | 2008-10-30 | Donald Kleinsek | Hair undifferentiated cells |
AU1472501A (en) * | 1999-11-05 | 2001-05-14 | Gerigene Medical Corporation | Augmentation and repair of age-related soft tissue defects |
US20090074729A2 (en) * | 1999-11-05 | 2009-03-19 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including fibroblasts |
US20080286242A2 (en) * | 1999-11-05 | 2008-11-20 | Donald Kleinsek | Augmentation and repair of spincter defects with cells including mesenchymal cells |
US7799325B2 (en) * | 1999-11-05 | 2010-09-21 | Kleinsek Donald A | Removal of hypertrophic scars |
CN1471586A (zh) | 2000-03-02 | 2004-01-28 | 罗切斯特大学 | 在三维生物反应器中生产来自体内的功能性白血病细胞 |
US7338657B2 (en) * | 2001-03-15 | 2008-03-04 | Biosphere Medical, Inc. | Injectable microspheres for tissue construction |
AU2001249221A1 (en) | 2000-03-20 | 2001-10-03 | Biosphere Medical, Inc. | Injectable and swellable microspheres for tissue bulking |
US6436424B1 (en) * | 2000-03-20 | 2002-08-20 | Biosphere Medical, Inc. | Injectable and swellable microspheres for dermal augmentation |
ATE327783T1 (de) | 2000-03-20 | 2006-06-15 | Biosphere Medical Inc | Injizierbare mikrokügelchen für den gewebeaufbau |
US6638312B2 (en) | 2000-08-04 | 2003-10-28 | Depuy Orthopaedics, Inc. | Reinforced small intestinal submucosa (SIS) |
US8366787B2 (en) * | 2000-08-04 | 2013-02-05 | Depuy Products, Inc. | Hybrid biologic-synthetic bioabsorbable scaffolds |
DE60121450T2 (de) * | 2000-08-16 | 2007-02-15 | Duke University | Mittels gewebetechnologie hergestellte dezellularisierte gegenstände und gewebe |
MXPA03001914A (es) | 2000-09-01 | 2004-05-24 | Univ Virginia Commonwealth | Matrices basadas en fibrina electroprocesada y tejidos. |
US20090130066A1 (en) * | 2000-11-06 | 2009-05-21 | Gerigene Medical Corporation | Augmentation and repair of sphincter defects with cells including muscle cells |
US7311905B2 (en) | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
IL156303A0 (en) | 2000-12-06 | 2004-01-04 | Robert J Hariri | Method of collecting placental stem cells |
US7041868B2 (en) | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Bioabsorbable wound dressing |
ES2548591T3 (es) | 2001-02-14 | 2015-10-19 | Anthrogenesis Corporation | Placenta post-parto de mamífero, su uso y células madre placentarias de la misma |
EP2336300B1 (en) | 2001-02-14 | 2015-07-08 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
JP4201134B2 (ja) * | 2001-07-16 | 2008-12-24 | デピュイ・プロダクツ・インコーポレイテッド | 軟骨修復装置および方法 |
WO2003007790A2 (en) | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Hybrid biologic/synthetic porous extracellular matrix scaffolds |
US8092529B2 (en) | 2001-07-16 | 2012-01-10 | Depuy Products, Inc. | Meniscus regeneration device |
US7819918B2 (en) * | 2001-07-16 | 2010-10-26 | Depuy Products, Inc. | Implantable tissue repair device |
US8025896B2 (en) | 2001-07-16 | 2011-09-27 | Depuy Products, Inc. | Porous extracellular matrix scaffold and method |
WO2003007787A2 (en) * | 2001-07-16 | 2003-01-30 | Depuy Products, Inc. | Cartilage repair and regeneration device and method |
US8337537B2 (en) | 2001-07-16 | 2012-12-25 | Depuy Products, Inc. | Device from naturally occurring biologically derived materials |
US7201917B2 (en) | 2001-07-16 | 2007-04-10 | Depuy Products, Inc. | Porous delivery scaffold and method |
EP2186407A1 (en) | 2002-02-13 | 2010-05-19 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta and uses and methods of treatment using said cells |
WO2003072128A2 (en) * | 2002-02-22 | 2003-09-04 | Ebi, L.P. | Methods and compositions for treating bone or cartilage defects |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
KR100527623B1 (ko) * | 2002-06-01 | 2005-11-15 | 라이프코드인터내셔날 주식회사 | 세포외기질을 포함하는 인공장기 제조용 생분해성 고분자기질 및 그의 제조방법 |
US20040171147A1 (en) | 2002-11-26 | 2004-09-02 | Hariri Robert J. | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
IL156945A0 (en) * | 2003-07-15 | 2004-02-08 | Itzhak Tavori | Device and a method for orthopedic delivery of bone reconstruction medium |
US7326571B2 (en) * | 2003-07-17 | 2008-02-05 | Boston Scientific Scimed, Inc. | Decellularized bone marrow extracellular matrix |
CA2566765C (en) * | 2004-05-11 | 2011-08-23 | Synthasome Inc. | Hybrid tissue scaffolds containing extracellular matrix |
US20070190108A1 (en) * | 2004-05-17 | 2007-08-16 | Arindam Datta | High performance reticulated elastomeric matrix preparation, properties, reinforcement, and use in surgical devices, tissue augmentation and/or tissue repair |
EP1789536A2 (en) * | 2004-08-30 | 2007-05-30 | IKEN Tissue Therapeutics, Inc. | Cultured three dimensional tissues and uses thereof |
US7513866B2 (en) | 2004-10-29 | 2009-04-07 | Depuy Products, Inc. | Intestine processing device and associated method |
CA2612188A1 (en) * | 2005-06-17 | 2007-01-04 | Theregen, Inc. | Methods for treating ischemic tissue |
US20070065415A1 (en) * | 2005-09-16 | 2007-03-22 | Kleinsek Donald A | Compositions and methods for the augmentation and repair of defects in tissue |
CA2974249C (en) | 2005-10-13 | 2021-10-12 | Anthrogenesis Corporation | Immunomodulation using placental stem cells |
DK2471903T3 (en) | 2005-12-29 | 2018-05-28 | Anthrogenesis Corp | Placenta stem cell populations |
CN101389754A (zh) | 2005-12-29 | 2009-03-18 | 人类起源公司 | 胎盘干细胞和第二来源干细胞的联合培养 |
US20070178137A1 (en) * | 2006-02-01 | 2007-08-02 | Toby Freyman | Local control of inflammation |
ES2709205T3 (es) | 2006-10-23 | 2019-04-15 | Celularity Inc | Métodos y composiciones para el tratamiento de defectos óseos con poblaciones de células placentarias |
US7871440B2 (en) | 2006-12-11 | 2011-01-18 | Depuy Products, Inc. | Unitary surgical device and method |
NZ597779A (en) | 2007-02-12 | 2013-07-26 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
MX2009008559A (es) | 2007-02-12 | 2009-08-21 | Anthrogenesis Corp | Hepatocitos y condorcitos de celulas madre de la placenta adherentes, y poblaciones de celulas enriquecidas con celulas madre de la placenta cd34+, cd45-. |
US9200253B1 (en) | 2007-08-06 | 2015-12-01 | Anthrogenesis Corporation | Method of producing erythrocytes |
PT2203176E (pt) | 2007-09-28 | 2015-03-02 | Anthrogenesis Corp | Supressão de tumor utilizando perfusato placentário humano e células assassinas naturais intermédias derivadas de placenta humanas |
KR20170116221A (ko) | 2007-11-07 | 2017-10-18 | 안트로제네시스 코포레이션 | 조산 합병증의 치료에 있어서의 제대혈의 용도 |
PL2247285T3 (pl) | 2007-11-30 | 2014-11-28 | Rnl Bio Co Ltd | Komórkowy środek terapeutyczny na nietrzymanie moczu zawierający komórki macierzyste pochodzące z doczesnej |
WO2009073178A1 (en) * | 2007-12-03 | 2009-06-11 | Sanbio, Inc. | Extracellular matrix from pluripotent cells |
WO2009097559A1 (en) | 2008-01-30 | 2009-08-06 | Histogen, Inc. | Extracellular matrix compositions |
US20120089491A1 (en) * | 2008-07-02 | 2012-04-12 | Katia Weber | System and method of providing enhanced transaction data |
KR20180049231A (ko) | 2008-08-20 | 2018-05-10 | 안트로제네시스 코포레이션 | 개선된 세포 조성물 및 그의 제조 방법 |
NZ592726A (en) | 2008-11-19 | 2012-12-21 | Anthrogenesis Corp | Amnion derived adherent cells |
RU2631488C2 (ru) | 2009-07-10 | 2017-09-22 | Хистоджен, Инк. | Кондиционированная среда и композиции на основе внеклеточного матрикса из клеток, культивированных в гипоксических условиях |
ES2673726T3 (es) | 2010-01-05 | 2018-06-25 | Cell Constructs I, Llc | Biomateriales fabricados a partir de cabello humano |
AU2011209819A1 (en) | 2010-01-26 | 2012-08-16 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
TW202011974A (zh) | 2010-04-07 | 2020-04-01 | 美商安瑟吉納西斯公司 | 利用胎盤幹細胞之血管新生 |
CN107828727A (zh) | 2010-07-13 | 2018-03-23 | 人类起源公司 | 产生自然杀伤细胞的方法、由此获得的细胞群体及其用途 |
CN103830282A (zh) | 2010-11-12 | 2014-06-04 | 阿勒根公司 | 经代谢的经调节的生长培养基和使用方法 |
US20120171180A1 (en) | 2010-12-30 | 2012-07-05 | Sascha Abramson | Compositions comprising amnion derived adherent cells and platelet-rich plasma |
AR084754A1 (es) | 2010-12-30 | 2013-06-05 | Anthrogenesis Corp | Composiciones que comprenden celulas madre de placenta y plasma rico en plaquetas, y sus metodos de uso |
AU2011352036A1 (en) | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
EP2661243B1 (en) | 2011-01-06 | 2022-10-12 | Humacyte, Inc. | Tissue-engineered constructs |
WO2012166844A2 (en) | 2011-06-01 | 2012-12-06 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
JP2014531908A (ja) | 2011-10-14 | 2014-12-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 構造アッセンブリによる配列決定 |
US11021737B2 (en) | 2011-12-22 | 2021-06-01 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
US10227639B2 (en) | 2011-12-22 | 2019-03-12 | President And Fellows Of Harvard College | Compositions and methods for analyte detection |
BR112014027592A2 (pt) * | 2012-05-09 | 2017-06-27 | Koninklijke Philips Nv | método para prover uma interface de rastreamento médico para comunicação entre pelo menos uma ferramenta de rastreamento de intervenção e um aplicativo de intervenção orientada por imagem (igi), interface de rastreamento médico, e produto de programa de computador |
US9914967B2 (en) | 2012-06-05 | 2018-03-13 | President And Fellows Of Harvard College | Spatial sequencing of nucleic acids using DNA origami probes |
EP3622960A1 (en) | 2013-02-05 | 2020-03-18 | Celularity, Inc. | Natural killer cells from placenta |
EP2971184B1 (en) | 2013-03-12 | 2019-04-17 | President and Fellows of Harvard College | Method of generating a three-dimensional nucleic acid containing matrix |
CN108474022A (zh) | 2015-11-03 | 2018-08-31 | 哈佛学院董事及会员团体 | 用于包含三维核酸的基质容积成像的设备和方法 |
CN109415761B (zh) | 2016-04-25 | 2022-09-20 | 哈佛学院董事及会员团体 | 用于原位分子检测的杂交链反应方法 |
CN105920679B (zh) * | 2016-04-26 | 2018-10-19 | 青岛大学 | 一种具有三维梯度孔结构的皮肤支架材料的制备方法 |
GB2569252A (en) | 2016-08-31 | 2019-06-12 | Harvard College | Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing |
CN109983125A (zh) | 2016-08-31 | 2019-07-05 | 哈佛学院董事及会员团体 | 生成用于通过荧光原位测序检测的核酸序列文库的方法 |
CN109789167A (zh) | 2017-04-14 | 2019-05-21 | 哈佛学院董事及会员团体 | 用于产生细胞衍生的微丝网络的方法 |
US11718829B2 (en) | 2017-07-28 | 2023-08-08 | Breakthrough Tech Llc | Methods and compositions for manufacturing extracellular matrix |
WO2020028194A1 (en) | 2018-07-30 | 2020-02-06 | Readcoor, Inc. | Methods and systems for sample processing or analysis |
CN111084788A (zh) * | 2018-10-22 | 2020-05-01 | 上海蓝盎电子科技发展有限公司 | 人工细胞间质 |
CN115006597B (zh) * | 2022-06-02 | 2024-01-19 | 上海威高医疗技术发展有限公司 | 一种口腔修复膜及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3949073A (en) * | 1974-11-18 | 1976-04-06 | The Board Of Trustees Of Leland Stanford Junior University | Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution |
US4424208A (en) * | 1982-01-11 | 1984-01-03 | Collagen Corporation | Collagen implant material and method for augmenting soft tissue |
US4582640A (en) * | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
US4837285A (en) * | 1984-03-27 | 1989-06-06 | Medimatrix | Collagen matrix beads for soft tissue repair |
US5288617A (en) * | 1984-10-31 | 1994-02-22 | Commonwealth Scientific And Industrial Research Organization | Method of producing an antigenic preparation |
US5460939A (en) * | 1986-04-18 | 1995-10-24 | Advanced Tissue Sciences, Inc. | Temporary living skin replacement |
US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5160490A (en) * | 1986-04-18 | 1992-11-03 | Marrow-Tech Incorporated | Three-dimensional cell and tissue culture apparatus |
US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US5266480A (en) * | 1986-04-18 | 1993-11-30 | Advanced Tissue Sciences, Inc. | Three-dimensional skin culture system |
US4721096A (en) * | 1986-04-18 | 1988-01-26 | Marrow-Tech Incorporated | Process for replicating bone marrow in vitro and using the same |
US4803075A (en) * | 1986-06-25 | 1989-02-07 | Collagen Corporation | Injectable implant composition having improved intrudability |
JPH041118Y2 (ja) * | 1986-07-31 | 1992-01-14 | ||
GB8708009D0 (en) * | 1987-04-03 | 1987-05-07 | Clayton Found Res | Injectable soft tissue augmentation materials |
US5342765A (en) * | 1991-08-01 | 1994-08-30 | Occidental Chemical Corporation | Method of producing extracellular products from aerobic microorganisms |
US5204382A (en) * | 1992-02-28 | 1993-04-20 | Collagen Corporation | Injectable ceramic compositions and methods for their preparation and use |
US5478739A (en) * | 1992-10-23 | 1995-12-26 | Advanced Tissue Sciences, Inc. | Three-dimensional stromal cell and tissue culture system |
US5541106A (en) * | 1993-04-05 | 1996-07-30 | Desmos, Inc. | Cell matrix stimulated attachment and hemidesmosome assembly |
US5397352A (en) * | 1993-08-27 | 1995-03-14 | Burres; Steven | Method of recollagenation |
US5516532A (en) * | 1994-08-05 | 1996-05-14 | Children's Medical Center Corporation | Injectable non-immunogenic cartilage and bone preparation |
-
1995
- 1995-06-06 US US08/470,101 patent/US5830708A/en not_active Expired - Lifetime
-
1996
- 1996-06-06 AU AU62609/96A patent/AU708090B2/en not_active Expired
- 1996-06-06 EP EP96921369A patent/EP0967934B1/en not_active Expired - Lifetime
- 1996-06-06 KR KR1019970708695A patent/KR19990022216A/ko not_active Application Discontinuation
- 1996-06-06 AT AT96921369T patent/ATE290350T1/de not_active IP Right Cessation
- 1996-06-06 DE DE69634454T patent/DE69634454T2/de not_active Expired - Lifetime
- 1996-06-06 CA CA002223892A patent/CA2223892A1/en not_active Abandoned
- 1996-06-06 WO PCT/US1996/009482 patent/WO1996039101A1/en active Search and Examination
- 1996-06-06 NZ NZ311313A patent/NZ311313A/xx unknown
- 1996-06-06 ES ES96921369T patent/ES2238076T3/es not_active Expired - Lifetime
- 1996-06-06 JP JP50179097A patent/JP3709487B2/ja not_active Expired - Lifetime
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004523484A (ja) * | 2000-11-17 | 2004-08-05 | ヴァージニア コモンウェルス ユニバーシティ インテレクチュアル プロパティー ファンデーション | 電気処理されたコラーゲン |
JP2005211099A (ja) * | 2004-01-27 | 2005-08-11 | Olympus Corp | 人工臓器構成材および人工臓器構成体の製造方法および人工臓器 |
JP2010511375A (ja) * | 2005-12-01 | 2010-04-15 | エイジェンシー フォー サイエンス,テクノロジー アンド リサーチ | 組織工学の足場としての三次元再構成細胞外マトリクス |
JP2012508739A (ja) * | 2008-11-14 | 2012-04-12 | ヒストジェン インコーポレイテッド | がんの処置のための細胞外マトリックス組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP0967934A4 (en) | 2001-11-28 |
NZ311313A (en) | 2000-05-26 |
DE69634454D1 (de) | 2005-04-14 |
DE69634454T2 (de) | 2006-05-11 |
EP0967934A1 (en) | 2000-01-05 |
US5830708A (en) | 1998-11-03 |
AU708090B2 (en) | 1999-07-29 |
ATE290350T1 (de) | 2005-03-15 |
ES2238076T3 (es) | 2005-08-16 |
JP3709487B2 (ja) | 2005-10-26 |
KR19990022216A (ko) | 1999-03-25 |
AU6260996A (en) | 1996-12-24 |
CA2223892A1 (en) | 1996-12-12 |
WO1996039101A1 (en) | 1996-12-12 |
EP0967934B1 (en) | 2005-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3709487B2 (ja) | 自然分泌細胞外マトリックスのための組成物及び方法 | |
US6284284B1 (en) | Compositions and methods for production and use of an injectable naturally secreted extracellular matrix | |
US5919702A (en) | Production of cartilage tissue using cells isolated from Wharton's jelly | |
AU715282B2 (en) | Method for making and/or repairing cartilage | |
AU689605B2 (en) | Three-dimensional cartilage cultures | |
US5041138A (en) | Neomorphogenesis of cartilage in vivo from cell culture | |
US5736372A (en) | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure | |
RU2523339C2 (ru) | Композиции внеклеточного матрикса для лечения рака | |
JP2004531297A (ja) | 組織修復のための方法および装具 | |
WO1999052572A1 (en) | Methods and compositions for tissue regeneration | |
CN1735685A (zh) | 用未分化的间充质细胞治疗组织 | |
WO2001003750A1 (en) | Human naturally secreted extracellular matrix-coated device | |
Rowland et al. | Factors influencing the long-term behavior of extracellular matrix-derived scaffolds for musculoskeletal soft tissue repair | |
US20210254008A1 (en) | Conditioned medium from cells cultured under hypoxic conditions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040519 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040705 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040824 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20041115 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050531 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050712 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050726 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090819 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100819 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110819 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110819 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120819 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120819 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130819 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |